MFM-223（人乳腺癌細胞）
CBP60388
詢 價
索取STR
產品描述
產品數(shù)據(jù)庫
| I. General information | |
| Synonyms: | MFM-223 |
| Background: | established from the pleural effusion of a post-menopausal breast cancer patient without any prior treatment (tumor: widespread ductal mammary carcinoma T4 N2 M1 with histological grade III); cells were described in the literature to express androgen, estrogen and progesterone receptors |
| Species: | human (Homo sapiens) |
| Tissue: | breast |
| Disease: | breast carcinoma |
| Gender: | N/A |
| Morphology: | adherent cells growing as monolayer with reticulate growth pattern; |
| Growth Mode: | N/A |
| Doubling Time: | ca. 5-7 days |
| DNA Profile: | N/A Cobioer’s Cell Line Authentication Service |
| Culture Medium: |
MEM + 10%FBS+ 1% Non Essential Amino Acids (NEAA) + 1mM Sodium Pyruvate (NaP) MFM-223完全培養(yǎng)基，# CBP60388M |
| Cryopreservation medium: | 90%FBS+10%DMSO |
| Mycoplasma: | negative in DAPI, microbiological culture, RNA hybridization, PCR assays |
| Immunology: | cytokeratin +, cytokeratin-7 +, cytokeratin-8 +, cytokeratin-17 -, cytokeratin-18 +, cytokeratin-19 +, desmin -, endothel -, EpCAM +, GFAP -, neurofilament -, vimentin - |
| Fingerprint: | multiplex PCR of minisatellite markers revealed a unique DNA profile |
| Species: | confirmed as human with IEF of AST, MDH |
| Cytogenetics: | human highly rearranged near-diploid karyotype with 12% polyploidy - 46(45-46)<2n>X, -X, -2, -5, -6, +7, -9, -10, +11, +12, -14, -15, -16, -17, -18, -19, -22, +10mar, add(5)(p15), der(7)?inv(7)(q1?q2?)dup(7)(q31q35), add(7)(q11;hsr), der(7)add(7)(p22)add(7)(q31-32), add(8)(p22-23), add(8)(q?24), del(10)(q2?), add(11)(q22), dup(12)(q13q14), add(13)(p11), add(15)(p11), add(17)(p1?), add)19)(q13), add(21)(p11), add(?22)(q13) - carries multiple hsr including ch 7 material - resembles published karyotype |
| Virus | ELISA: reverse transcriptase negative; PCR: EBV -, HBV -, HCV -, HIV-1 -, HIV-2 -, HTLV-I/II -, MLV -, SMRV - |
| Comments: | For more information, please contact Cobioer (4008-750-250). |
